Source: https://www.global-regulation.com/law/australia/222506/national-health-%2528efficient-funding-of-chemotherapy%2529-special-arrangement-amendment-instrument-2014-%2528no.-8%2529-%2528no.-pb-64-of-2014%2529.html
Timestamp: 2019-02-22 12:19:06
Document Index: 45776257

Matched Legal Cases: ['art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1']

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 8) (No. PB 64 of 2014) (Australia)
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 8) (No. PB 64 of 2014)
Link to law: https://www.comlaw.gov.au/Details/F2014L01124
PB 64 of 2014
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 8)
Dated 19 August 2014
(1) This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.8).
(2) This Instrument may also be cited as PB 64 of 2014.
[1] Schedule 1 Part 1 entry for ‘Carboplatin’ in each of the forms ‘Solution for I.V. injection 150 mg in 15 mL’; ‘Solution for I.V. injection 450 mg in 45 mL’; and ‘Solution for I.V. injection 50 mg in 5 mL’ with manner of administration Injection:
[2] Schedule 1 Part 1, entry for ‘Epirubicin’ in the form ‘Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL’ with manner of administration Injection/Intravesical:
omit from the column headed ‘Brand’: Epirubicin Actavis 200 substitute: Epirubicin ACT
omit from the column headed ‘Responsible Person’: UA substitute: VN
[3] Schedule 1 Part 1, entry for ‘Epirubicin’ in the form ‘Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL’ with manner of administration Injection/Intravesical:
omit from the column headed ‘Brand’: Epirubicin Actavis 50 substitute: Epirubicin ACT
[4] Schedule 1 Part 1 after the entry for ‘Fludarabine’ in the form ‘Powder for I.V. injection containing fludarabine phosphate 50 mg’ with manner of administration Injection and Brand ‘Fludara’:
[5] Schedule 1 Part 1 after the entry for ‘Gemcitabine’ in the form ‘Powder for I.V. infusion 200 mg (as hydrochloride)’ with manner of administration Injection:
Solution concentrate for I.V. infusion 1 g
(as hydrochloride) in 25 mL
[6] Schedule 1 Part 1 after the entry for ‘Gemcitabine’ in the form ‘Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL’ with manner of administration Injection:
Solution concentrate for I.V. infusion 2 g
(as hydrochloride) in 50 mL
Solution concentrate for I.V. infusion 200 mg
(as hydrochloride) in 5 mL
[7] Schedule 1 Part 1 entry for ‘Irinotecan’ in the form ‘I.V injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL’ with manner of administration Injection:
[8] Schedule 1 Part 1 entry for ‘Oxaliplatin’ in each of the forms ‘Powder for I.V. infusion 100 mg’; and ‘Powder for I.V. infusion 50 mg’ with manner of administration Injection:
[9] Schedule 2 after the entry for ‘Ondansetron’ in each of the forms ‘Tablet 4 mg (as hydrochloride dihydrate)’; and ‘Tablet 8 mg (as hydrochloride dihydrate)’ with manner of administration Oral and Brand ‘APO‑Ondansetron’:
[10] Schedule 2 after the entry for ‘Ondansetron’ in each of the forms ‘Tablet (orally disintegrating) 4 mg’; and ‘Tablet (orally disintegrating) 8 mg’ with manner of administration Oral:
[11] Schedule 3, Responsible Person codes, after entry for BX:
21 147 854 484